Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.
Lijie ZhouCai ZhangXiong YangLilong LiuJunyi HuYaxin HouHong TaoHaruhiko SugimuraZhaohui ChenLiang WangKe ChenPublished in: Clinical and translational medicine (2022)
Our findings provide novel preclinical and clinical information about the role of melatonin in advanced PCa and characterize the importance of enzalutamide combined with MLT administration as a therapy for advanced PCa.